The ME/CFS Collaborative Research Center (previously known as the CFS Research Center) at Stanford University was established in 2014 and is part of the Stanford Genome Technology Center. Both centers are directed by Ronald W. Davis, PhD, Professor of Biochemistry and of Genetics at Stanford.
Throughout his career, Dr. Davis has conducted cutting edge, innovative, interdisciplinary research and technology development on cancer, immunology, genetics, infectious disease, novel drug development, and nanofabrication of diagnostic instruments. His emphasis has always been to increase accuracy and decrease cost. He has made significant contributions to research on numerous organisms, including bacteria, yeast, plants and humans.
Dr. Davis was the first to physically map the genome of any organism (1968).
Dr. Davis discovered a simple way to join together DNA from two organisms (“sticky ends”), and was the first to generate a hybrid DNA molecule that could replicate inside of cells (DNA cloning).
He developed most of the technology for the molecular genetics of yeast, which made it the most advanced model for conducting molecular genetics research. Metadescription: Ron Davis discusses how DNA & RNA technology is being developed at Stanford to advance research into ME/CFS, Long COVID, and related diseases.
Robert Phair, PhD gives a video update on the Itaconate Shunt Hypothesis for ME/CFS, a study in collaboration with Christopher W. Armstrong, Ron Davis, PhD, and Ron’s team at Stanford.
Ron Davis Updates on the Metabolic Trap! From the Desk of Ronald W. Davis, PhD: I’m pleased to be doing this series of interviews posted
The goal of the project is to develop, characterize, and validate a microfluidic chip for the estimation of biomechanical properties of red blood cells (RBCs) isolated from ME/CFS patients vis-à-vis healthy controls.
This project aims to test whether genetic markers and other indicators of BH4 deficiency are also present in subjects with Long COVID.
The goal of this study was to extend the Severely ill Patient Study and conduct a comprehensive “Big Data” analysis on ME/CFS patients and their families.
The study’s objective was to establish the role of T cells and the immune system in ME/CFS by examining the genetic material in T cells — immune cells that identify and kill infected cells.
The goal of the Severely ill Patient Study was to conduct a comprehensive “Big Data” analysis on severely ill ME/CFS patients in order to begin an exploration to find the molecular basis of ME/CFS.
The aim of this study was to test the hypothesis developed by Dr. Phair that a crucial component of metabolism in ME/CFS patients appears to be “trapped” in an unhealthy state.
Developing Blood-Based Diagnostic
and Drug Screening Technology
This technology demonstrates a significant difference between ME / CFS patients and healthy controls.
This could be a very inexpensive and effective diagnostic test for ME/CFS.
This work has been accepted for publication in Clinical Hemorheology and Microcirculation and also has been accepted as an abstract for the American Society of Hematology 60th Annual Meeting.
The technology will be optimized for easy clinical adoption and scaled up so that numerous FDA-approved drugs can be simultaneously screened as potential treatments.
Director
Ronald W. Davis, PhD, Professor of Biochemistry and Genetics, Stanford University School of Medicine; Director, Stanford Genome Technology Center; Director, Chronic Fatigue Syndrome Research Center at Stanford University; Chair, Open Medicine Foundation ME/CFS Scientific Advisory Board.
Collaborative Research Center / Stanford Genome Technology Center
Robert Phair, PhD
Wenzhong Xiao, PhD
Mohsen Nemat-Gorgani, PhD
Peidong Shen, PhD
Laurel Crosby, PhD
Michael Jensen
Fereshteh Jahaniani, PhD
Gozde Durmus, PhD
Julie Wilhelmy
Alex Kashi
Anand Ramasubramanian, PhD
Amit Saha, PhD
Layla Cervantes
Ami Mac, MD
David Kaufman, MD
Bela Chheda, MD
Chris Armstrong, PhD
Katrina Hong
Anna Okumu
Ashley Haugen
Collaborators
Juan Santiago, PhD
Eric Shaqfeh, PhD
Mark M. Davis, PhD
Michael Sikora
Mike Snyder, PhD
Craig Heller, PhD
Lars Steinmetz, PhD
Jonas Bergquist, MD, PhD
Rahim Esfandyarpour, PhD
Curt Scharfe, MD
Robert Naviaux, MD, PhD
William Robinson, MD
Lucinda Bateman, MD
Jennifer Frankovich, MD
In Memoriam – Ron Tompkins, MD, ScD
Please help us expand our research efforts across the globe. Every donation brings us closer to a fully-funded research effort and the answers we all seek.
OMF is a non-profit 501(c)(3) organization
(EIN# 26-4712664). All donations are tax-deductible to the extent allowed by law.
Open Medicine Foundation®
29302 Laro Drive, Agoura Hills, CA 91301 USA
Phone: 650-242-8669
info@omf.ngo
Copyright © 2023 Open Medicine Foundation. All Rights Reserved.
What are the advantages of giving from your Donor Advised Fund (DAF)?
How do I make a donation through my DAF?
Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.
Still can’t find your fund?
Donate your appreciated stock directly to OMF and you can receive an immediate income-tax deduction for the fair market value of the securities on the date of transfer (even if you originally paid much less for them).Gifting of Stock
Broker: Schwab
DTC #: 0164
Account #: 47083887
Account Registered as:
Open Medicine Foundation
29302 Laro Drive
Agoura Hills, CA 91301
Please speak to your personal tax advisor and then email or call OMF at 650-242-8669 to notify us of your donation or with any questions.
